Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.
NCT03766750 · EMS · PHASE3 · withdrawn · last registry update 2022-07-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, EMS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DPP4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-15Phase 3 first posted: Tanta University, Ursodeoxycholic acid (NCT05902468)
- 2023-06-05Results posted on the registry: Sabyasachi Sen, Dapagliflozin 10mg + Saxagliptin 5mg (NCT03660683)
- 2023-06-05Also stopped (terminated): Sabyasachi Sen, Dapagliflozin 10mg + Saxagliptin 5mg (NCT03660683)
- 2023-06-02Phase 3 first posted: EMS, LID104 + Dapagliflozin (NCT05886088)
- 2023-04-07Also stopped (suspended): Oregon Health and Science University, Saxagliptin (NCT01527747)
- 2023-03-23Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL067 + Alogliptin (NCT05782192)
- 2023-02-21Results posted on the registry: University at Buffalo, Linagliptin + Placebo (NCT02372630)
- 2023-02-16Also stopped (terminated): Erasme University Hospital, Incretinomimetics + DPP-4 inhibitors (NCT02244164)
- 2023-01-19Results posted on the registry: George Washington University, Linagliptin + Placebo (NCT02467478)
- 2022-12-07Phase 3 first posted: Huashan Hospital, Insulin Degludec and Insulin Aspart (NCT05641337)
- 2022-11-15Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Exendin 9-39 and Sitagliptin + Placebo (NCT02697253)
- 2022-10-19Results posted on the registry: Takeda, Alogliptin Benzoate + Placebo (NCT02856113)
- 2022-08-17Phase 3 first posted: Handok Inc., Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet + Teneligliptin Placebo Oral Tablet (NCT05504226)
- 2022-08-17Phase 3 first posted: Handok Inc., Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet + Teneligliptin Placebo Oral Tablet (NCT05504239)
- 2022-08-16Results posted on the registry: Vanderbilt University Medical Center, Liraglutide + Sitagliptin (NCT03101930)
- 2022-07-21Results posted on the registry: University at Buffalo, Januvia (Sitagliptin) 100 mg + Placebo (NCT00659711)
- 2022-05-31Also stopped (terminated): AstraZeneca, Dapagliflozin 10 mg + Dapagliflozin 5 mg (NCT03608358)
- 2022-05-11Phase 3 first posted: Tanta University, Alpha lipoic acid + Roflumilast (NCT05369793)
- 2022-03-24Also stopped (withdrawn): University at Buffalo, sitagliptin + Placebo (NCT01741103)
- 2022-03-22Phase 3 first posted: National University of Malaysia, Dipeptidyl-Peptidase IV Inhibitors (NCT05290506)
- 2022-03-14Results posted on the registry: Population Health Research Institute, insulin glargine + sitagliptin/metformin (NCT02623998)
- 2022-02-09Results posted on the registry: University of Pennsylvania, Sitagliptin + Placebo (NCT01879228)
- 2022-02-02Phase 3 first posted: University of Milan, Sitagliptin (NCT05219409)
- 2022-01-28Results posted on the registry: Tanabe Pharma Corporation, Teneligliptin 20mg + Placebo (NCT02916706)
- 2022-01-28Results posted on the registry: Tanabe Pharma Corporation, Teneligliptin 20mg + Placebo (NCT02924064)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision